RISANKIZUMAB (Skyrizi®)
Clinical Indication
Moderate to severe plaque psoriasis
Comments
In line with NICE TA596
Date of classification
June 2019
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.